Emergent BioSolutions Reports Financial Results for Full Year 2010
2010 revenues of $286.2 million
2010 net income of $51.7 million, or $1.63 per share, representing ninth consecutive year of profitability
2010 cash, investments and accounts receivable balance of $210.4 million
2011 forecast reaffirmed: total revenues of $320 to $340 million and net income of $35 to $45 million
Emergent BioSolutions Inc. (NYSE: EBS) announced on 10 March its [...]
April 13, 2011
Tags: Anthrax vaccines, Biothrax, Business, Chief financial officer, Emergent BioSolutions, Financial Results Posted in: Board of Directors, Business, Chief executive officer, Emergent BioSolutions, Financial Results, fuad el-hibri 
No Comments
Emergent BioSolutions Inc., Q2 2009 Earnings Call Transcript
Emergent BioSolutions Inc., (EBS)
Q2 2009 Earnings Call
August 6, 2009 5:00 pm ET
Executives
Robert G. Burrows – Vice President, Investor Relations
Fuad El-Hibri – Chairman of the Board, Chief Executive Officer
R. Don Elsey – Chief Financial Officer
Daniel J. Abdun-Nabi – President, Chief Operating Officer
W. James Jackson, Ph.D. – Senior Vice President and Chief Scientific Officer
Analysts
Eric Schmidt [...]
August 14, 2009
Tags: Business, Chairman, Chief executive officer, Chief financial officer, Chief operating officer, Emergent BioSolutions, finance, fuad el-hibri, Investor relations, Shareholders, US government, Vice president Posted in: Board of Directors, CEO, Emergent BioSolutions, Management, Shareholders, fuad, fuad el-hibri No Comments